"CTLA-4 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
| Descriptor ID |
D060908
|
| MeSH Number(s) |
D12.776.543.750.705.222.750 D23.050.301.264.894.158 D23.101.100.894.158
|
| Concept/Terms |
CTLA-4 Antigen- CTLA-4 Antigen
- Antigen, CTLA-4
- CTLA 4 Antigen
- Antigens, CD152
- CD152 Antigens
- Cytotoxic T-Lymphocyte-Associated Antigen 4
- Cytotoxic T Lymphocyte Associated Antigen 4
- Cytotoxic T-Lymphocyte Antigen 4
- Cytotoxic T Lymphocyte Antigen 4
- CD152 Antigen
- Antigen, CD152
|
Below are MeSH descriptors whose meaning is more general than "CTLA-4 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- CTLA-4 Antigen [D12.776.543.750.705.222.750]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CTLA-4 Antigen [D23.050.301.264.894.158]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CTLA-4 Antigen [D23.101.100.894.158]
Below are MeSH descriptors whose meaning is more specific than "CTLA-4 Antigen".
This graph shows the total number of publications written about "CTLA-4 Antigen" by people in this website by year, and whether "CTLA-4 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "CTLA-4 Antigen" by people in Profiles.
-
Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors. J Geriatr Oncol. 2022 09; 13(7):1003-1010.
-
Activation of T cell checkpoint pathways during ?-cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes. Immunology. 2022 07; 166(3):341-356.
-
The evolving landscape of immunotherapy in solid tumors. J Surg Oncol. 2021 Mar; 123(3):798-806.
-
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. J Immunother Cancer. 2019 09 18; 7(1):252.
-
Engineered Dendritic Cell-Directed Concurrent Activation of Multiple T cell Inhibitory Pathways Induces Robust Immune Tolerance. Sci Rep. 2019 08 19; 9(1):12065.
-
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Ra Complexes Enhances Tumor Control. Cancer Immunol Res. 2019 08; 7(8):1371-1380.
-
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018 07 11; 6(1):69.
-
Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Aug 01; 127(8):3052-3064.
-
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Sci Adv. 2017 May; 3(5):e1602133.
-
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunol Res. 2017 01; 5(1):84-91.